Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ImmuFact (eftilagimod alpha)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

EOC Pharma, Immutep

Drug class:

APC activator, MHC II agonist

‹

›

PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab + eftilagimod alpha Sensitive: B - Late Trials pembrolizumab + eftilagimod alpha Sensitive : B	pembrolizumab + eftilagimod alpha Sensitive: B - Late Trials pembrolizumab + eftilagimod alpha Sensitive : B
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	eftilagimod alpha Sensitive: B - Late Trials eftilagimod alpha Sensitive : B	eftilagimod alpha Sensitive: B - Late Trials eftilagimod alpha Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	eftilagimod alpha Sensitive: C2 – Inclusion Criteria eftilagimod alpha Sensitive : C2	eftilagimod alpha Sensitive: C2 – Inclusion Criteria eftilagimod alpha Sensitive : C2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + eftilagimod alpha Sensitive: C3 – Early Trials pembrolizumab + eftilagimod alpha Sensitive : C3	pembrolizumab + eftilagimod alpha Sensitive: C3 – Early Trials pembrolizumab + eftilagimod alpha Sensitive : C3
CD163 overexpression	Solid Tumor	CD163 overexpression	Solid Tumor	avelumab + eftilagimod alpha Sensitive: C3 – Early Trials avelumab + eftilagimod alpha Sensitive : C3	avelumab + eftilagimod alpha Sensitive: C3 – Early Trials avelumab + eftilagimod alpha Sensitive : C3
PTPRC overexpression	Solid Tumor	PTPRC overexpression	Solid Tumor	avelumab + eftilagimod alpha Sensitive: C3 – Early Trials avelumab + eftilagimod alpha Sensitive : C3	avelumab + eftilagimod alpha Sensitive: C3 – Early Trials avelumab + eftilagimod alpha Sensitive : C3
PTPRC overexpression	Solid Tumor	PTPRC overexpression	Solid Tumor	eftilagimod alpha Sensitive: C3 – Early Trials eftilagimod alpha Sensitive : C3	eftilagimod alpha Sensitive: C3 – Early Trials eftilagimod alpha Sensitive : C3
CD163 overexpression	Solid Tumor	CD163 overexpression	Solid Tumor	eftilagimod alpha Sensitive: C3 – Early Trials eftilagimod alpha Sensitive : C3	eftilagimod alpha Sensitive: C3 – Early Trials eftilagimod alpha Sensitive : C3
PD-L1 overexpression	Solid Tumor	PD-L1 overexpression	Solid Tumor	avelumab + eftilagimod alpha Sensitive: C3 – Early Trials avelumab + eftilagimod alpha Sensitive : C3	avelumab + eftilagimod alpha Sensitive: C3 – Early Trials avelumab + eftilagimod alpha Sensitive : C3
PD-L1 overexpression	Solid Tumor	PD-L1 overexpression	Solid Tumor	eftilagimod alpha Sensitive: C3 – Early Trials eftilagimod alpha Sensitive : C3	eftilagimod alpha Sensitive: C3 – Early Trials eftilagimod alpha Sensitive : C3